Your browser doesn't support javascript.
loading
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Rousselot, Philippe; Mollica, Luigina; Guilhot, Joëlle; Guerci, Agnès; Nicolini, Franck E; Etienne, Gabriel; Legros, Laurence; Charbonnier, Aude; Coiteux, Valérie; Dartigeas, Caroline; Escoffre-Barbe, Martine; Roy, Lydia; Cony-Makhoul, Pascale; Dubruille, Viviane; Gardembas, Martine; Huguet, Françoise; Réa, Delphine; Cayssials, Emilie; Guilhot, François; Bergeron, Anne; Molimard, Mathieu; Mahon, Francois-Xavier; Cayuela, Jean-Michel; Busque, Lambert; Bouchet, Stéphane.
Afiliación
  • Rousselot P; Department of Hematology and Oncology, Centre Hospitalier de Versailles, Le Chesnay, France.
  • Mollica L; UMR1184, IDMIT Department Université Paris-Saclay, Commissariat à l'énergie atomique et aux énergies alternatives, University of Versailles Saint-Quentin-en-Yvelines, Montigny-Le-Bretonneux, France.
  • Guilhot J; Department of Hematology, Hôpital Maisonneuve-Rosemont, University of Montréal, Montréal, Québec, Canada.
  • Guerci A; Inserm CIC 1402 CHU de Poitiers, Poitiers, France.
  • Nicolini FE; Department of Hematology, CHU Brabois Vandoeuvre, Nancy, France.
  • Etienne G; Department of Hematology, Centre Léon Bérard, Lyon, France.
  • Legros L; Department of Hematology, Institut Bergonié, Bordeaux, France.
  • Charbonnier A; Department of Hematology, Hôpital Paul Brousse, Villejuif, France.
  • Coiteux V; Department of Hematology, Institut Paoli Calmette, Marseille, France.
  • Dartigeas C; Department of Hematology, Hôpital Huriez - CHRU, Lille, France.
  • Escoffre-Barbe M; Department of Hematology, CHU de Tours, Tours, France.
  • Roy L; Department of Hematology, Centre Hospitalier Pontchaillou, Rennes, France.
  • Cony-Makhoul P; Department of Hematology, Hôpital Henri Mondor, AP-HP, Créteil, France.
  • Dubruille V; Department of Hematology, Centre Hospitalier Annecy Genevois, Pringy, France.
  • Gardembas M; Department of Hematology, Hôpital Hôtel-Dieu, CHU de Nantes, Nantes, France.
  • Huguet F; Department of Hematology, CHU d'Angers, Angers, France.
  • Réa D; Department of Hematology, Institut Universitaire du Cancer - Oncopole, Toulouse, France.
  • Cayssials E; Department of Hematology, Hôpital Saint-Louis et EA3518, AP-HP, Paris, France.
  • Guilhot F; Inserm CIC 1402 CHU de Poitiers, Poitiers, France.
  • Bergeron A; Department of Hematology, CHU de Poitiers, Poitiers, France.
  • Molimard M; Inserm CIC 1402 CHU de Poitiers, Poitiers, France.
  • Mahon FX; Department of Pneumology, Hôpital Saint-Louis, AP-HP, Paris, France.
  • Cayuela JM; Clinical Pharmacology Department, Centre Hospitalier Pellegrin, CHU de Bordeaux, Bordeaux, France.
  • Busque L; University of Bordeaux Ségalen, Bordeaux, France.
  • Bouchet S; Department of Hematology, Institut Bergonié, Bordeaux, France.
Br J Haematol ; 194(2): 393-402, 2021 07.
Article en En | MEDLINE | ID: mdl-34195988
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Derrame Pleural / Leucemia Mielógena Crónica BCR-ABL Positiva / Monitoreo de Drogas / Inhibidores de Proteínas Quinasas / Dasatinib / Antineoplásicos Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Br J Haematol Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Derrame Pleural / Leucemia Mielógena Crónica BCR-ABL Positiva / Monitoreo de Drogas / Inhibidores de Proteínas Quinasas / Dasatinib / Antineoplásicos Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Br J Haematol Año: 2021 Tipo del documento: Article